Two Sigma Securities’s ZyVersa Therapeutics ZVSA Stock Holding History

Two Sigma Securities’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,121	Closed	-$23.4K	–	3786
2024 Q1	$23.4K	Buy	3,121 +1,254	+67%	+$9.45K	﹤0.01%	2658
2023 Q4	$16.8K	Buy	+1,867	New	+$52.5K	﹤0.01%	2749
2023 Q3	–	Sell	-113	Closed	-$9.7K	–	3572
2023 Q2	$9.7K	Buy	+113	New	+$29.7K	﹤0.01%	2602

Other funds holding ZVSA

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Securities's ZVSA Position: Q2 2024 in Review

Two Sigma Securities sold out of ZyVersa Therapeutics (ZVSA) in Q2 2024, closing a stake of 3,121 shares — an estimated $23.4K sold.

Two Sigma Securities first reported a position in ZVSA in Q2 2023 and held it in 3 quarters. The position peaked at $23.4K in Q1 2024. 4 funds tracked by Wall St. Rank hold ZVSA as of Q2 2024.

Two Sigma Securities reported no remaining ZyVersa Therapeutics position as of Q2 2024 after selling out during the quarter.
Two Sigma Securities sold 3,121 ZyVersa Therapeutics shares in Q2 2024, an estimated $23.4K.
Two Sigma Securities first reported a position in ZyVersa Therapeutics in Q2 2023 and held it in 3 quarters.
Two Sigma Securities's ZyVersa Therapeutics position peaked at $23.4K in Q1 2024.
4 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q2 2024.

Based on Two Sigma Securities's 13F filing for Q2 2024, filed 14 Aug 2024.